Both low and high ankle-brachial index are considered as indicators of systemic atherosclerosis in older HIV-negative adults. Whether those ankle-brachial index values are predictors of atherosclerosis in HIV-positive subjects remains unknown. We measured ankle-brachial index in 139 HIV-infected patients and compared the results obtained with carotid intima-media thickness, a well established marker of subclinic atherosclerosis. Ankle-brachial index was associated with carotid intima-media thickness. Patients with low anklebrachial index, but not those with high anklebrachial index, had high carotid intima-media thickness.
Cardiovascular disease (CVD) is of growing concern in HIV-infected patients receiving antiretroviral therapy [1] . Given the usual late onset of clinical events in the course of systemic atherosclerosis, clinicians caring for HIV-infected patients with significant cardiovascular risk would welcome disease surrogate markers. In the general population, carotid intima-media thickness (IMT) measured by ultrasonography has shown to correlate with coronary atherosclerosis [2] , and it has been directly associated with an increased risk of myocardial infarction and stroke in older adults without a history of cardiovascular disease [3] . Carotid IMT measurement, however, is fairly expensive and not readily available. An alternative noninvasive imaging modality is ankle-brachial index (ABI), a simple and inexpensive diagnostic test that is a powerful indicator of systemic atherosclerosis and peripheral vascular disease and a strong predictor of death from cardiovascular causes in HIV-negative adults [4, 5] . However, most previous studies validating ABI were performed in older adults with a high prevalence of diabetes [6] [7] [8] . Therefore, the significance of the cut-off points derived from those populations for younger patients with a lower prevalence of diabetes, such as HIV-infected subjects, remains unknown.
We investigated subclinic atherosclerosis by measuring both ABI and carotid IMT in HIV-infected patients. We studied the association between both techniques and the relationship of the abnormal values with cardiovascular risk factors and with factors associated with HIV infection.
Study participants were HIV-infected patients who were cared for in our HIV clinic from January 2006 to October 2007. The investigation was approved by the Ethics Committee for Clinical Research. A total of 139 patients gave their informed consent to perform both techniques. Clinical and laboratory data were obtained at the visit. Cardiovascular risk factors were defined according to the National Cholesterol Education Program [9] .
To calculate the ABI, measurements of systolic arterial pressure (SAP) were obtained from bilateral brachial, dorsalis pedis, and posterior tibial arteries using a blood pressure cuff and a Doppler probe (SmartdopTM 30; Hayashi Denki Co. Ltd, Kawasaki, Japan). When the two brachial SAP differed, the highest reading was used as the denominator. To calculate the ABI of each leg, the ABI numerator used was the highest pressure measured (dorsalis pedis or posterior tibial) from that leg. The lowest ABI value was used to classify the patient into an ABI category. For determining the carotid IMT, B-mode high-resolution ultrasound was used following a standard procedure as described previously [10] . To quantify the degree of carotid artery wall thickening, the mean of six measures performed in the posterior wall of the left common carotid artery was taken.
We used the Mann-Whitney U-test to compare continuous variables and Fisher's exact test or x 2 test for categorical variables. The cut-off point of greater than 0.8 mm was used to define a high IMT [3, 11] . For ABI, the currently accepted cut-off point of less than 0.90, which is associated with a two-to three-fold increased risk of cardiovascular morbidity and mortality [4, 5] , was used to define an abnormal (low) value. As an increased cardiovascular disease mortality with ABIs greater than 1.40 has recently been demonstrated [6] , an analysis of patients with ABI greater than 1.40 was also conducted. The discriminative power of other ABI cut-off points was also explored using receiver operating characteristic (ROC) curves and the IMT values as gold standard. The association of abnormal values of both techniques with cardiovascular risk factors and with factors associated with HIV infection was examined by univariate analysis. Correlations between HIV-1 plasma viral load and either IMT and ABI measurements were described using the Spearman correlation coefficient. Forward stepwise multiple linear regression models were constructed to estimate the prediction of IMT values by traditional cardiovascular risk factors, HIV-1 plasma viral load, and ABI measurements. Statistical analyses were performed using SPSS, version 12.0 (Chicago, Illinois, USA). ) had three or more risk factors. No significant correlations were found between HIV-1 plasma viral load and IMT or ABI measurements, either in all patients (r ¼ 0.173, P ¼ 0.063; and r ¼ À0.078, P ¼ 0.406, respectively) or in those with 0-1 cardiovascular risk factor (r ¼ À0.084, P ¼ 0.539; r ¼ À0.13, P ¼ 0.103, respectively). Thirty (21.58%) of the 139 patients had a carotid IMT greater than 0.8 mm. Patients with carotid IMT greater than 0.8 mm were older [median, interquartile range (IQR)], 57.65 (47.34-70.68) years vs. 43.28 (37.67-47.42) years; P < 0.001], had a higher frequency of hypertension (73 vs. 20%; P < 0.001) and dyslipidaemia (80.7 vs. 25.71%; P < 0.001), a higher Framingham score [17 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) vs. 4 (1-10); P < 0.001], were less likely to be current smokers (46.15 vs. 68.57%; P ¼ 0.019), and tended to have a lower CD4 cell count [410 (227-582) vs. 460 (307-740) cells/ml; P ¼ 0.164] than those with lower IMT. Considering the IMT as the dependent variable, multiple linear regression analysis that included age, hypertension, dislipidemia, current smoker status, ABI, Framingham score, and HIV-1 plasma viral load indicated ABI (standardized beta, À0.175), hypertension (standardized beta, þ0.277), and age (standardized beta, þ0.411) as the best predictors (adjusted r 2 ¼ 0.362; P < 0.001). When only patients with two or more cardiovascular risk factors were included in the analyses, ABI (standardized beta, À0.231), hypertension (standardized beta, þ0.433), current smoker status (standardized beta, þ0.339), and age (standardized beta, þ0.542) were also the best predictors of IMT (adjusted r 2 ¼ 0.312; P < 0.001).
Associations between ABI and carotid IMT are shown in Table 1 . According to ROC analysis, the ABI cut-off point of less than 0.90 had the best discriminatory power between patients with normal and abnormal carotid IMT. All patients with ABI less than 0.90 were men, they had higher carotid IMT [0.95 (0.83-1.07) vs. 0.66 (0.58-0.78) mm; P ¼ 0.005], more traditional cardiovascular risk factors [4 (2.5-4.7) vs. 2 (1-3); P ¼ 0.015], and lower CD4 cell count [220 (54.7-267.5) vs. 450 (310-710) cells/ml; P ¼ 0.009] than those with ABI greater than 0.90.
No differences were seen in the carotid IMT between patients with high (>1.40) and normal (0.90-1.39) ABI. When patients with two or more cardiovascular risk factors were analysed separately, those with high (>1.40) ABI had lower total cholesterol levels [160.5 (102. .2) vs. 207 (174.2-243.5) mg/dl; P ¼ 0.024], lower LDL cholesterol levels [80.5 (48.7-120.5) vs. 135 (102.5-155.5) mg/dl; P ¼ 0.01], and a lower Framingham score [6.5 (3.7-10) vs. 11 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ; P ¼ 0.02] than subjects with normal ABI.
We found that patients with low ABI, according to the accepted cut-off point value for general population (<0.90), had a high carotid IMT, suggesting that, in HIVinfected patients, this value may indeed be a surrogate marker of subclinical atherosclerosis. Despite having a very low sensitivity, its high specificity makes it a clinically meaningful predictor for indicating patients with high IMT. In contrast, we did not find an association between high (>1.40) ABI and carotid IMT measurements. Moreover, patients with two or more cardiovascular risk factors and ABI greater than 1.40 had lower LDL cholesterol levels and lower Framingham score than those with normal ABI. That cut-off point was associated with increased cardiovascular disease mortality among the Strong Heart Study in which the participants were American Indians, older, and with a much higher prevalence of diabetes than the HIV-infected patients included in the present study [6] .
Our present study did not address the clinical impact of the ABI measurements but, given its simplicity and high 1370 AIDS 2008, Vol 22 No 11 positive predictive value, we believe that they might have implications for management of individual HIV-infected patients with cardiovascular risk factors. Although our observations need to be confirmed in large longitudinal studies with clinical endpoints, the data support the current recommendation for HIV-negative patients with an ABI less than 0.90 to be implemented in HIV-infected patients [9] ; an aggressive approach to risk factors modification aimed to delay the progression of subclinical atherosclerosis is warranted in those patients. Suppression of HIV replication using highly active antiretroviral therapy (HAART) might influence chemokine (C-C motif) receptor 5 expression on infected cells and therefore modulate the activity of chemokine (C-C motif) receptor 5 antagonists. Chemokine (C-C motif) receptor 5 expression was examined longitudinally in 26 HIV-infected adults who initiated HAART. Long-term suppression of plasma HIV-RNA did not significantly influence chemokine (C-C motif) receptor 5 expression on T lymphocytes. Therefore, the activity of chemokine (C-C motif) receptor 5 antagonists should not differ before and following HIV suppression on HAART.
Impact of antiretroviral therapy on chemokine
The chemokine (C-C motif) receptor 5 (CCR5) acts as coreceptor for HIV entry into target cells and therefore plays a major role in HIV pathogenesis [1] [2] [3] [4] . Expression of CCR5 on the surface of T lymphocytes varies among individuals [4] . CCR5 expression has been directly associated with disease progression in HIV-infected patients; those who express high number of CCR5 molecules at the surface of CD4þ T lymphocytes tend to show high viral load, increased immune activation and low CD4 cell counts [5] [6] [7] . Scarce and controversial data are available about the effect of highly active antiretroviral therapy (HAART) on CCR5 expression on T lymphocytes. If CCR5 upregulation is linked to immune activation, a decrease of CCR5 expression could be expected following diminished immune activation as a result of HIV suppression under HAART [8, 9] . By contrast, similar CCR5 expression before and after HAART could suggest that CCR5 expression is not influenced by viral replication and it could be more inherent to each individual [5] . CCR5 antagonists are a new class of antiretroviral drugs, which inhibit viral entry blocking the interaction between the viral envelope gp120 and the CCR5 coreceptor. So far, maraviroc (MVC) is the only CCR5 antagonist approved for clinical use [10] . Given its mechanism of action, the level of CCR5 expression may affect the antiviral activity of these compounds [11] . Herein, we examine whether longterm control of HIV replication under HAART could impact on CCR5 expression on CD4þ T lymphocytes in a group of HIV-infected individuals.
CCR5 expression was examined in 11 healthy controls and 26 HIV-1-infected adults who initiated HAART and maintained plasma HIV-RNA below 50 copies/ml during at least 2 years. The level of CCR5 expression (measured as the proportion of positive cells) and density (measured as molecules/cell on CCR5þ cells) were examined on naïve (CD45ROÀ) and memory (CD45ROþ) CD4þ and CD8þ T-cell subsets. (Fig. 1) . (P < 0.0001). In addition, memory T cells showed higher levels of CCR5 expression than naïve T cells, in both CD4þ and CD8þ T lymphocytes (P < 0.0001). By contrast, no differences in the density of CCR5 expression were observed when comparing naïve with memory subsets of T cells in infected and uninfected individuals. Although some prior studies [7, 8, 12] had reported an association between T-cell activation in CD4þ and CD8þ T cells and CCR5 expression in the absence of HAART, we did not confirm that observation. The distinct methodologies used to detect and measure immune activation [7, 8] could explain the differences seen between those studies and our findings.
The level and density of CCR5 expression was significantly higher on total CD8þ T cells than in total CD4þ T cells in both HIV patients and healthy controls
After initiating HAART, CCR5 density on CD4þ T cells remained significantly increased in patients compared to controls even after 24 months of successful HAART. By contrast, the level of CCR5 on memory CD8þ T cells tended to increase with HAART and, as a consequence, the proportion of CD8þ CD45ROþ CCR5þ cells was similar in patients and controls at months 12 and 24 of HAART ( Fig. 1 ). Our results are in line with the findings of Reynes et al. [13] and differ from the results obtained in other studies [8, 9] with shorter follow ups in which significant decreases in CCR5 density on CD4þ and CD8þ T cells were seen in HIV patients under successful HAART for 12-28 weeks. A different evolution of CCR5 expression depending on the length of follow-up after HAART initiation could explain these differences.
As expected, CD38 expression levels significantly decreased from baseline to months 12 and 24 in both CD4þ [4201 (2220), 3839 (1756), 3286 (967) molecules/ cell, respectively; P ¼ 0.021) and CD8þ T cells [4395 ([3687), 1795 (1536), 1399 (894) molecules/cell, respectively; P ¼ 0.005). Thus, we found a different evolution of CD38 expression and CCR5 expression, which is in line with the lack of association between these two parameters at baseline.
In summary, these results suggest that long-term suppression of HIV replication with HAART does not significantly influence CCR5 expression on CD4þ and CD8þ T lymphocytes. Therefore, the activity of CCR5 antagonists should not differ in a given HIV-infected individual before and following control of HIV replication with HAART. We report a case of the nucleoside reverse transcriptase inhibitors, stavudine and lamivudine inducing Fanconi syndrome in a patient. The presence of simultaneous lactic acidosis suggests mitochondrial toxicity within the proximal renal tubular cells as the likely pathogenesis. We recommend that both the above nucleosides be added to the list of antiretroviral drugs that can induce Fanconi syndrome and that patients on stavudine and lamivudine be monitored carefully for early signs of Fanconi syndrome.
Proximal renal tubular dysfunction or Fanconi syndrome in HIV-infected patients is typically associated with the nucleotide reverse transcriptase inhibitor, tenofovir [1] . Nucleoside analogues are associated with mitochondrial toxicity, which may manifest as lactic acidosis; nephrotoxicity of nucleoside analogues is rare. In particular, stavudine has a good renal safety profile and only one previous case of Fanconi syndrome has been reported with lamivudine and stavudine [2] . We report here a case of both Fanconi syndrome and lactic acidosis in an HIV-infected patient receiving an antiretroviral regimen including stavudine and lamivudine.
A 42-year-old Kenyan lady with advanced HIV disease presented with a 2-week history of generalized weakness and, 2 days into admission, developed difficulty in breathing. This was not associated with any systemic symptoms such as cough, chest pain or orthopnoea. She had initiated treatment with stavudine, lamivudine, nevirapine and prophylactic cotrimoxazole 9 months prior to admission. Clinical examination revealed an unwell obese lady in respiratory distress. She was afebrile and dehydrated. She was tachypnoeic at 30 breaths per minute and tachycardic at 109 beats per minute. Her blood pressure was raised at 145/95 mmHg. The rest of the examination was unremarkable.
Laboratory evaluation revealed a haemoglobin concentration of 14.2 gm/dl, a white blood cell count of 12 500 cells/ml and a platelet count of 284 000 cells/ml. The serum sodium concentration was 135 mmol/l, serum chloride was 101 mmol/l, serum potassium was low at 2.5 mmol/l, blood urea nitrogen concentration was 2.2 mmol/l, serum creatinine concentration was 90 mmol/l and serum glucose concentration was 8 mmol/l. Liver enzymes, calcium, protein, plasma creatinine phosphokinase and troponin T levels were normal. An arterial blood gas analysis revealed a high anion gap metabolic acidosis with a pH of 7.15, serum bicarbonate of 2 OmM, partial pressure of carbon dioxide of 6 mmHg, partial pressure of oxygen of 114 mmHg, oxygen saturation of 97 on 2l% oxygen via nasal cannula, anion gap of 32 and markedly elevated lactate levels of 52.7 mg/ml (4.5-19.8) . ECG revealed a sinus tachycardia and chest radiograph was normal. Her CD4 þ T-helper lymphocyte count measured 59 cells/ml and HIV viral load was fewer than 50 copies/ml.
Highly active antiretroviral therapy was discontinued and the acidosis improved with intravenous isotonic sodium bicarbonate. The patient continued to have hypokalaemia and hypophosphatemia despite replacement. Further investigations revealed a persistent glucosuria, phosphaturia and aminoaciduria in keeping with a proximal renal tubular dysfunction. Clinically, she continued to improve and was discharged with a normalized serum pH. She is currently being followed up in the outpatient clinic and continues to improve.
The anion gap acidosis in this patient was attributed to elevated lactate levels resulting from stavudine. Stavudine, a thymidine nucleoside analogue, is now rarely used in developed countries but is still widely used in developing countries owing to its low cost and inclusion in generic fixed combinations. A recognized side effect of stavudine is hyperlactaemia. Hyperlactaemia seen in nucleoside reverse transcriptase inhibitor (NRTI)-treated patients ranges from asymptomatic infection to severe lactic acidosis. Lactic acidosis is uncommon but has a high mortality rate. Although the incidence of mild hyperlactaemia has been reported to be as high as 20% of NRTI-treated patients, the incidence of symptomatic severe hyperlactaemia was lower at 1.3-3.9 cases per 1000 treated person-years [3] . Interestingly, its presence does not predict the development of subsequent lactic acidosis. All NRTIs have been implicated in lactic acidosis but the risk is greatest with didanosine followed, in decreasing order, by stavudine and zidovudine [4] . The risk of lactic acidosis is greatest with the combination of stavudine and didanosine or tenofovir and didanosine. Other reported risk factors for developing lactic acidosis include female sex, pregnancy, obesity, low nadir CD4 cell count prior to the initiation of therapy, renal insufficiency and coinfection with hepatitis B or C [5, 6] .
Lactic acidosis is thought to be mediated through mitochondrial toxicity; NRTIs inhibit mitochondrial DNA gamma polymerase, an essential enzyme for mitochondrial DNA replication, leading to mitochondrial DNA depletion. Other NRTI-related side effects associated with damage to mitochondrial DNA include myopathy, peripheral neuropathy, pancreatitis and lipodystrophy [7] .
Treatment involves immediate discontinuation of the causative NRTIs. For more severe cases, supportive care in the ICU with intravenous bicarbonate, haemodialysis and ventilatory support may be required. Treatment with cofactors required for oxidative phosphorylation which are thought to protect against mitochondrial damage, such as L-carnitine, thiamine, riboflavin, coenzyme Q and antioxidants has been advocated but has not been proven effective in clinical trials [8] .
Acquired Fanconi syndrome is characterized by a generalized defect in proximal tubular function leading to impaired resorption with subsequent aminoaciduria, glycosuria with normal serum glucose, hypokalaemia and phosphate wasting. Osteomalacia is common in Fanconi syndrome secondary to chronic phosphate loss and inadequate synthesis of 1,25(OH) 2 vitamin D resulting in failure to mineralize bone. There is also a defective bicarbonate resorption by the proximal tubule resulting in a hyperchloraemic normal anion gap metabolic acidosis.
Acquired Fanconi syndrome in the context of HIV infection has been most commonly associated not only with the use of the nucleotide reverse transcriptase inhibitor, tenofovir [1, [9] [10] [11] , but also with the other acyclic nucleotide phosphonates, cidofovir [12] and highdose adevofir [13] . The nucleoside reverse transcriptase inhibitors, abacavir [14] and didanosine [15] , have also been implicated in several case reports. Other types of renal injury reported with the use of reverse transcriptase inhibitors include acute tubular necrosis, distal tubular acidosis and nephrogenic diabetes insipidus.
Toxicities associated with stavudine include mitochondrial toxicity. In contrast, renal toxicity of nucleoside analogues, including stavudine and lamivudine, is far less common despite their extensive use over the years. Only one other case of renal tubular acidosis and hypophosphataemia has been associated with the above two nucleoside analogues [2] . Renal elimination accounts for 40% of the overall clearance of stavudine, whereas approximately 70% of lamivudine taken orally is eliminated renally. It is likely that the lactic acidosis and proximal tubular dysfunction demonstrated in this case was secondary to treatment with nucleoside reverse transcriptase inhibitors. Implication of the other drugs concurrently received by the patient is less likely. Renal tubular disorders have not been reported with nevirapine. Distal rather than proximal tubular acidosis and hyperkalaemia may complicate high-dose cotrimoxazole treatment.
Nucleotide analogues, cidovofir, adefovir, and tenofovir, have been shown to induce nephrotoxicity by its accumulation within proximal renal tubular cells [13, 16] . The exact pathogenesis of Fanconi syndrome in this patient is uncertain but is likely due to stavudine-induced or lamivudine-induced depletion of mitochondrial DNA in the renal tubular cells leading to mitochondrial dysfunction. This is supported by the patient's coexistent presentation of lactic acidosis.
The toxicity in Fanconi syndrome has been found to be mostly reversible on stopping the offending drug. Renal biopsy is rarely necessary but may be indicated if symptoms and biochemical abnormalities do not resolve after stopping the drug.
